This is believed to lead to quicker triglyceride hydrolysis and glycerol release
Management of Local Anesthetic Emergencies The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patients state of consciousness after each local anesthetic injection
Sensitive skin Challenges: Retinol causes more irritation Even gentle peptides may sting on compromised barrier Strategy: Start with low-dose retinol (0.25% or 0.3%) Use soothing peptides (Matrixyl, copper peptides) Apply retinol 2-3x weekly initially Use sandwich method (moisturizer retinol peptides moisturizer) Consider separate AM/PM application Dry skin Challenges: Retinol increases dryness Needs extra hydration Strategy: Use hydrating peptide serums with hyaluronic acid Apply retinol over damp skin Heavy moisturizer after peptides + retinol Consider retinol in emollient base (like squalane) Oily/acne-prone skin Advantages: Tolerates retinol well (less dryness) Retinol helps with breakouts Strategy: Can use higher retinol concentrations (0.5-1%) Lighter peptide serums (water-based, not oil-heavy) Oil-free moisturizer Can apply peptides + retinol nightly once acclimated Mature skin (50+) Needs: More aggressive anti-aging May have thinner, more fragile skin Strategy: Build up to potent retinol (0.5-1%) gradually Use multiple peptide types (signal + copper + neurotransmitter) Apply peptides AM and PM Retinol PM only Rich, nourishing moisturizers Injectable peptides vs topical peptides with retinol Beyond topical skincare, some people use injectable peptides for anti-aging
20 Peptide-based therapeutics offer distinct advantages over conventional drugs, including high target specificity, enhanced safety profiles with minimal off-target effects, and low immunogenicity
Folic acid is more affected than 5-methyl-THF owing to the different affinities of FBP for various vitamers
CagriSema vs Tirzepatide (REDEFINE 4): strong weight loss, but an important endpoint miss Novo Nordisk has announced headline results from the open-label phase 3 REDEFINE 4 trial comparing CagriSema (cagrilintide + semaglutide) vs tirzepatide 15 mg in obesity
